Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis

米拉贝格伦 膀胱过度活动 医学 安慰剂 荟萃分析 随机对照试验 不利影响 排尿 托特罗定 夜尿症 泌尿科 内科学 泌尿系统 替代医学 病理
作者
Wenjuan He,Yuqian Zhang,Guangliang Huang,Yunfei Tian,Qian Sun,Xiuju Liu
出处
期刊:Luts: Lower Urinary Tract Symptoms [Wiley]
卷期号:15 (3): 80-88 被引量:6
标识
DOI:10.1111/luts.12475
摘要

Abstract Objectives The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder. Methods A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively. Results A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo. Conclusions Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
白白白完成签到 ,获得积分10
1秒前
桃酥完成签到,获得积分10
3秒前
土狗完成签到,获得积分10
3秒前
zhengzehong完成签到,获得积分10
3秒前
Rosaline完成签到 ,获得积分10
3秒前
小马完成签到,获得积分10
4秒前
尼古拉斯佩奇完成签到,获得积分10
4秒前
7秒前
大大大大黄完成签到,获得积分10
7秒前
入秋的杰尼龟完成签到,获得积分10
7秒前
薛布慧完成签到 ,获得积分10
7秒前
qn完成签到,获得积分10
9秒前
Dryad发布了新的文献求助30
10秒前
威武的飞阳完成签到,获得积分20
11秒前
Tokgo完成签到,获得积分10
12秒前
12秒前
mp5完成签到,获得积分10
12秒前
13秒前
云上人发布了新的文献求助10
13秒前
vv123456ha完成签到,获得积分10
15秒前
小王同学完成签到,获得积分10
15秒前
晚灯君完成签到 ,获得积分10
15秒前
16秒前
Annora完成签到,获得积分10
17秒前
研友_8oYg4n完成签到,获得积分10
18秒前
大卫在分享完成签到,获得积分0
18秒前
小颖发布了新的文献求助10
19秒前
19秒前
Anyemzl完成签到,获得积分10
20秒前
21秒前
zhao完成签到,获得积分10
21秒前
曰比的崛起完成签到,获得积分10
21秒前
怎么会睡不醒完成签到 ,获得积分10
22秒前
王梓磬完成签到,获得积分10
22秒前
阔达的黑猫完成签到 ,获得积分10
23秒前
左左右右完成签到 ,获得积分10
23秒前
zhaolee完成签到 ,获得积分10
23秒前
NexusExplorer应助土豆炖牛腩采纳,获得10
24秒前
25秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150700
求助须知:如何正确求助?哪些是违规求助? 2802232
关于积分的说明 7846614
捐赠科研通 2459579
什么是DOI,文献DOI怎么找? 1309294
科研通“疑难数据库(出版商)”最低求助积分说明 628849
版权声明 601757